ライフサイエンスコーパス: growth hormone

1 being nuclear RNA enriched and regulated by growth hormone.

2 tion of oleic acid and the overproduction of growth hormone.

3 ed Down syndrome, vitamin A derivatives, and growth hormone.

4 an RNA methyltransferase, and GH1, encoding growth hormone.

5 t be rescued by administration of ghrelin or growth hormone.

6 UAG, reduced DI and kg and increased plasma growth hormone.

7 -onset gigantism resulting from an excess of growth hormone.

8 clamps, increased plasma corticosterone and growth hormone.

9 sometimes associated with hypersecretion of growth hormone.

10 s for the mammatrophic hormones estrogen and growth hormone.

11 position, which may affect the regulation of growth hormones.

12 pond to inflammatory cytokines, insulin, and growth hormones.

13 A homozygous mutation in growth hormone 1 (GH1) was recently identified in an ind

14 Specifically, human growth hormone 1, murine ribosomal protein S27, and muri

15 After exclusion of 189 CCS treated with growth hormone, 9.2% (254 of 2,776) had a SAH.

16 MAPK inhibition and growth hormone: a promising therapy in XLH.

17 and IL-22, and hormonal modulation including growth hormone administration and sex steroid inhibition

18 ulation including sex steroid inhibition and growth hormone administration.

19 b, letrozole, Y-27632, octreotide, and human growth hormone, all delivered at clinically-relevant dos

20 Of these patients, 8374 of received growth hormone and 1267 did not.

21 GHSR controls, among others, growth hormone and insulin secretion, adiposity, feeding

22 s a G-protein-coupled receptor that controls growth hormone and insulin secretion, food intake, and r

23 sregulation of gene networks associated with growth hormone and insulin signaling, including inductio

24 The growth hormone and insulin-like growth factor (IGF) syst

25 hypothalamus and low expression of pituitary growth hormone and prolactin (prl).

26 ole for MIR205HG as an lncRNA that regulates growth hormone and prolactin production in the anterior

27 at GH3 cells, it led to increased release of growth hormone and proliferation of growth hormone-produ

28 gly, this period of growth is independent of growth hormone and the underlying mechanism is poorly un

29 aly is characterized by increased release of growth hormone and, consequently, insulin-like growth fa

30 od for the bacteria and the bacteria produce growth hormones and antibiotics for the algae, or parasi

31 red in the presence or the absence of IGF-1, growth hormone, and an IGF-1 receptor-blocking antibody.

32 nd prolactin deficiencies, whereas for ACTH, growth hormone, and antidiuretic hormone deficiency dyna

33 of thyroxine, hydrocortisone, sex steroids, growth hormone, and desmopressin.

34 Levels of insulin, cortisol, growth hormone, and noradrenaline, as well as hypoglycem

35 g MIR205HG had a temporal reduction in Pit1, growth hormone, and prolactin.

36 ma concentrations of 25 different cytokines, growth hormones, and other factors which have previously

37 able to solubilise phosphate, produce plant growth hormones, antagonise pathogens and fix N(2).

38 Treatment with growth hormone appears safe in the short term, while dat

39 ion, or lipid accumulation in these cells by growth hormone application.

40 roduction of insulin-like growth factor 1 or growth hormone, are involved in the pathogenesis of gluc

41 -microglobulin, immunoglobulin G1, and human growth hormone as model systems, we demonstrate that DEP

42 of ghrelin, which includes the secretion of growth hormone, as well as the stimulation of appetite,

43 Indeed, short-term treatment with growth hormone augmented senescent host liver repopulati

44 leads to the formation of a gradient of the growth hormone auxin across the photo-stimulated stem.

45 In plants, the growth hormone auxin induces stem elongation in response

46 The plant growth hormone auxin regulates development via a family

47 e directional, cell-to-cell transport of the growth hormone auxin to generate an asymmetric auxin res

48 ating glucose, altered lipid metabolism, and growth hormone axis perturbations, can promote senescent

49 ich may relate to contamination of different growth hormone batches with different strains of human p

50 onstrated functional complexation with human growth hormone binding protein (hGHBp) to the different

51 bances (leptin, afamin), stunting of growth (growth hormone binding protein), and connective tissue r

52 lant, early institution of recombinant human growth hormone can promote growth.

53 e inadequately controlled (5-point, 2 h mean growth hormone concentration >2.5 mug/L and insulin-like

54 hieving biochemical control, defined as mean growth hormone concentration less than 2.5 mug/L and nor

55 ous treatment (octreotide or lanreotide) and growth hormone concentrations at screening (2.5-10 mug/L

56 tion in childhood has been related to higher growth-hormone concentrations that may affect mammary gl

57 hood, with human cadaveric pituitary-derived growth hormone contaminated with prions.

58 the use of biological materials (e.g. human growth hormone) contaminated with prions.

59 ns of epinephrine, norepinephrine, glucagon, growth hormone, cortisol, endogenous glucose production,

60 UAG did not alter growth hormone, cortisol, glucagon, or free fatty acid l

61 Individual growth hormone deficiencies can develop after a dose as

62 The most common endocrine disorders were growth hormone deficiency (12.5%), precocious puberty (1

63 Growth hormone deficiency (GHD) after TBI may impair axo

64 yroid cancer (HR, 9.2; 95% CI, 6.2 to 13.7), growth hormone deficiency (HR, 5.3; 95% CI, 4.3 to 6.4),

65 dy aimed to quantify risk factors for SAH or growth hormone deficiency among CCS.

66 h whole-genome resequencing in patients with growth hormone deficiency and maternally inherited gingi

67 crinology clinic where he was diagnosed with growth hormone deficiency and was started on replacement

68 he regulation of human growth, and show that growth hormone deficiency associated with maternally inh

69 ment on fracture risk in adult patients with growth hormone deficiency exist.

70 treatment on fracture risk in patients with growth hormone deficiency from the international Hypopit

71 Familial growth hormone deficiency provides an opportunity to ide

72 ocus, in a large family in which an isolated growth hormone deficiency segregates as an autosomal dom

73 this prospective cohort study, patients with growth hormone deficiency were analysed from the HypoCCS

74 ive against fracture for adult patients with growth hormone deficiency without previously reported os

75 with adrenocorticotropic hormone deficiency, growth hormone deficiency, and mild ectodermal dysplasia

76 or older and had an established diagnosis of growth hormone deficiency, either alone or with multiple

77 Survivors had significantly more growth hormone deficiency, hypogonadism, and neuropathy

78 syndrome, coeliac disease, cystic fibrosis, growth hormone deficiency, renal tubular acidosis, and s

79 timum for bone health of adult patients with growth hormone deficiency.

80 hthalmia, hypogonadotrophic hypogonadism and growth hormone deficiency.

81 ynthesis and secretion of VLDL-TAG using the growth hormone-deficient Ames dwarf mouse model, which h

82 icit at 5 years was 55% (95% CI 41-67), with growth hormone deficit being most common.

83 up method, for the characterization of human growth hormone degradation products.

84 rns with muscularity and use of supplements, growth hormone derivatives, or anabolic steroids to achi

85 t source of infecting prion contamination of growth hormone derived from a patient with Creutzfeldt-J

86 In addition, growth hormone displayed a delayed response but to a hig

87 ase due to administration of cadaver-sourced growth hormone during childhood are still being seen in

88 Growth hormone enhances the recovery of hypoglycemia via

89 erentiated further into cholangiocytes using growth hormone, epidermal growth factor, interleukin-6,

90 xposure of young and old HSCs to recombinant growth hormone ex vivo led to diminished short-term reco

91 ta after systemic injections of contaminated growth hormone extracts or dura mater grafts derived fro

92 Accordingly, the administration of dTMP-growth hormone fusion protein led to a rapid platelet re

93 date genes in these two regions included the growth hormone gene (GH1) on SSC12 and PRKD1 on SSC7.

94 alar in food ingredients based on the salmon growth hormone gene 1 (GH1).

95 Life-long lack of growth hormone (GH) action can produce remarkable extens

96 Plasma growth hormone (GH) and hepatic autophagy each have been

97 he transmembrane domains of the receptors of growth hormone (GH) and insulin-like growth factor 1 (IG

98 During puberty, the serum levels of growth hormone (GH) and its downstream effector IGF-1 in

99 In humans, low levels of growth hormone (GH) and its mediator, IGF-1, associate w

100 finding is the unique expression pattern of growth hormone (Gh) and prolactin (Prl).

101 Both pathological excess and deficiency of growth hormone (GH) are associated with cardiovascular m

102 Levels of growth hormone (GH) are elevated in T1D, which aggravate

103 ats with monosodium glutamate (MSG), a total growth hormone (GH) blocker, and, using cultured hepatoc

104 However, growth hormone (GH) can also stimulate macrophage activa

105 hormone (FSH), luteinizing hormone (LH) and growth hormone (GH) cells.

106 Growth hormone (GH) deficiency and loss of physical acti

107 concomitant with increasing levels of serum growth hormone (GH) during natural GH cycles.

108 Growth hormone (GH) excess in acromegaly is associated w

109 Acromegaly is a human disease of growth hormone (GH) excess with considerable morbidity a

110 Growth hormone (GH) has an important function as an insu

111 somatotroph adenomas result in dysregulated growth hormone (GH) hypersecretion and acromegaly; howev

112 om mice that overexpress or are deficient in growth hormone (GH) indicate that GH stimulates T and B-

113 Growth hormone (GH) is a major metabolic homeostatic fac

114 Growth hormone (GH) is secreted during hypoglycemia, and

115 e potential dysfunction caused by changes in growth hormone (GH) levels after brain death (BD), and t

116 Growth hormone (GH) plays a significant role in normal r

117 ver disease (NAFLD) are reported to have low growth hormone (GH) production and/or hepatic GH resista

118 Treatment with recombinant human growth hormone (GH) promotes longitudinal growth and lik

119 dies have shown that PVH neurons express the growth hormone (GH) receptor (GHR), although the role of

120 Ghrelin is a peptide hormone that stimulates growth hormone (GH) release and positive energy balance

121 Growth hormone (GH) resistance has been associated with

122 Gonadal steroids modulate growth hormone (GH) secretion and the pubertal growth sp

123 Classical studies suggest that growth hormone (GH) secretion is controlled by negative-

124 cate until now that the pulsatile pattern of growth hormone (GH) secretion is primarily controlled by

125 s is shaped by the male pattern of pituitary growth hormone (GH) secretion that determines body size

126 a close relationship between food intake and growth hormone (GH) secretion; however, the mechanism th

127 Sex-dependent pituitary growth hormone (GH) secretory profiles-pulsatile in male

128 Here we show that central growth hormone (GH) signaling also promotes neuroendocri

129 s have underscored the importance of hepatic growth hormone (GH) signaling in the development of NAFL

130 Growth hormone (GH) signaling is required for promoting

131 Disruption of hepatocyte growth hormone (GH) signaling through disruption of Jak2

132 ytokine signaling 2 (SOCS2), an inhibitor of growth hormone (GH) signaling, was strongly induced afte

133 transcription factor STAT5 in liver impairs growth hormone (GH) signalling and thereby promotes fatt

134 study investigates the efficacy of systemic growth hormone (GH) therapy in ameliorating the deleteri

135 expression is transcriptionally regulated by growth hormone (GH) through growth hormone response elem

136 The ability of growth hormone (GH) to induce adipose tissue lipolysis h

137 f iatrogenic Creutzfeldt-Jakob disease after growth hormone (GH) treatment provide an opportunity to

138 We also examined links between ghrelin and growth hormone (GH), a major downstream effector of the

139 Levels of pituitary growth hormone (GH), a metabolic homeostatic factor with

140 Growth hormone (GH), a pleiotropic hormone secreted by t

141 pituitary hormones such as prolactin (PRL), growth hormone (GH), adrenocorticotropic hormone (ACTH),

142 ising minimum cortisol and high aldosterone, growth hormone (GH), and prolactin levels, thereby presu

143 Pediatric patients have been treated with growth hormone (GH), and recent findings suggest that bl

144 ncentration of circulating hormones, such as growth hormone (GH), but the biological functions of thi

145 Growth hormone-releasing hormone (GHRH) and Growth hormone (GH), underappreciated findings in ARID1B

146 n is mediated by a marked increase in plasma growth hormone (GH), which is elicited by an increase in

147 ggest that loss of MC4R function may enhance growth hormone (GH)-mediated growth, although this remai

148 hagic obesity, central hypogonadism, and low growth hormone (GH).

149 BA; 20 ppm in feed) or Reporcin (recombinant growth hormone; GH; 10 mg/48 hours injected) and compare

150 on, and activity levels) and deficiencies in growth hormone (GHD) and/or sex steroids with low BMD an

151 with cotton DELLA, GhSLR1, repressor of the growth hormone gibberellin (GA).

152 Using human growth hormone (hGH) and human leptin (hLeptin) as model

153 eric dynamics by conducting studies on human growth hormone (hGH) and pyrin domain (PYD), and the res

154 and tissue-specific activation of the human growth hormone (hGH) gene cluster in the pituitary and p

155 The human growth hormone (hGH) gene is controlled by a long-range

156 Human growth hormone (hGH) is known to play a functional role

157 The human growth hormone (hGH) minigene used for transgene stabili

158 The human Growth Hormone (hGH) multigene cluster contains five gen

159 , we contrast IgG binding with that of human growth hormone (hGH) to its receptor (hGH-R) which displ

160 Ectopic human growth hormone (hGH) was highly expressed in MIP-CreERT

161 Human growth hormone (hGH), and its receptor interaction, is e

162 estigated the weak self-association of human growth hormone (hGH, KD = 0.90 +/- 0.03 mM) at neutral p

163 leaf closure has been associated with plant growth hormones, how mechanical forces actuate the proce

164 These findings suggest that the growth hormone/IGF-I system may be a potential therapeut

165 Mechanistically, direct upregulation of the growth hormone IGF2 emerged as a mediator of the aggress

166 previously unrecognized role for ghrelin and growth hormone in maladaptive changes following prolonge

167 ke growth factor 2 (IGF2) is the major fetal growth hormone in mammals.

168 findings demonstrate the functional role of growth hormone in promoting thrombopoiesis and provide a

169 characterizing the interaction between human growth hormone in solution and the corresponding antibod

170 n (adrenocorticotropic hormone, cortisol and growth hormone) increased in spring in both strains but

171 nitial step in the biosynthesis of the plant growth hormone indole-acetic acid by bacterial pathogens

172 Igf-1 transcription is regulated through growth hormone-induced, JAK2 kinase-mediated phosphoryla

173 which carry single-gene mutations within the growth-hormone, insulin/IGF-1 or mTOR signalling pathway

174 e mice promotes growth while suppressing the growth hormone-insulin-like growth factor-1 (GH-IGF-1) a

175 oduction and associates with abrogation of a growth hormone/insulin-like growth factor 1 (GH/IGF1) ax

176 As IGFBP3 plays a key role in regulating the growth hormone/insulin-like growth factor type 1 (GH/IGF

177 We identified dysregulation of the Growth Hormone/Insulin-like Growth Factor-1 (GH/IGF-1) p

178 Growth hormone is disrupted most often, followed by gona

179 Increased secretion of growth hormone leads to gigantism in children and acrome

180 Moreover, nitrate increased circulating growth hormone levels in humans and rodents.

181 crosis factor-alpha, cortisol, glucagon, and growth hormone levels increased, and free fatty acids an

182 Growth hormone levels were significantly higher in juven

183 ated insulin-like growth factor 1 levels and growth hormone levels; initial treatment is surgical.

184 ed important biological functions related to growth, hormone levels affecting female fertility, physi

185 as evidenced by increased plasma ghrelin and growth-hormone levels.

186 study was to test whether fasting levels of growth hormone measured with a high-sensitivity assay (h

187 escent host liver repopulation involving the growth hormone-mediated release of the transcriptional b

188 Loss of growth hormone-mediated signal transducer and activator

189 nile than in senescent rats, suggesting that growth hormone might promote host liver repopulation.

190 *05, DQB1*02, DQB1*03:02 alleles), and human growth hormone (positive control).

191 lease of growth hormone and proliferation of growth hormone-producing cells.

192 ne disease, and the use of recombinant human growth hormone provide some hope for catch-up growth in

193 a co-chaperone and regulator of androgen and growth hormone receptor (AR, GHR) signalling.

194 This includes down-regulation of growth hormone receptor (GHR) and of STAT5 signaling, wh

195 Growth hormone receptor (GHR) and prolactin receptor (PR

196 Growth hormone receptor (Ghr) signaling is important in

197 rtial hepatectomy by preventing increases in growth hormone receptor (GHR) via ubiquitination, suppre

198 lication FDR-corrected p = 2.18 x 10-2), and growth hormone receptor (GHR, Discovery FDR-corrected p

199 with phosphorylated peptides from substrates growth hormone receptor (GHR-pY595) and erythropoietin r

200 re variation in Europeans and for genes with growth hormone receptor and regulation functions.

201 and pasireotide), dopamine agonists and the growth hormone receptor antagonist pegvisomant.

202 ul5-Rbx2 (CRL5(SOCS2)), binds phosphorylated growth hormone receptor as its main substrate.

203 .SIGNIFICANCE STATEMENT People and mice with growth hormone receptor deficiency (GHRD or Laron syndro

204 Growth hormone receptor deficiency (GHRD) results in sho

205 es using beads decorated with phosphorylated growth hormone receptor peptides.

206 ncident type 2 diabetes were aminoacylase-1, growth hormone receptor, and insulin-like growth factor-

207 ased on an archetypal cytokine receptor, the growth hormone receptor.

208 ons, as well as sex-biased binding sites for growth hormone-regulated transcriptional activators (STA

209 including two rat lincRNAs showing the same growth hormone-regulated, sex-biased expression as their

210 for five transcription factors implicated in growth hormone-regulated, sex-biased liver gene expressi

211 states, transcription factor occupancy, and growth hormone regulation provides novel insights into t

212 ghrelin, responsible for the stimulation of growth hormone release and appetite, little is known of

213 sly revealed promising results in inhibiting growth hormone release in pituitary somatotrophs.

214 GHSR1a enhances growth hormone release, appetite, and dopamine signaling

215 to circulation, affecting energy balance and growth hormone release.

216 uteinizing hormone releasing hormone (LHRH), growth hormone releasing hexapeptide (GHRP-6), and TrpCa

217 elanocortin (POMC), neuropeptide Y (NPY) and growth hormone releasing hormone (GHRH) neurons, regulat

218 s LHn from serotype D with a fragment of the growth hormone releasing hormone, has previously reveale

219 Azapeptide analogues of growth hormone releasing peptide-6 (GHRP-6) exhibit prom

220 Because growth hormone-releasing hormone (GHRH) and GHRH recepto

221 ) deficiency with inadequate compensation by Growth hormone-releasing hormone (GHRH) and Growth hormo

222 therapeutic effects of agonistic analogs of growth hormone-releasing hormone (GHRH) and their mechan

223 Growth hormone-releasing hormone (GHRH) antagonist MIA-6

224 The strong inhibitory activities of growth hormone-releasing hormone (GHRH) antagonists have

225 Finally, we also detected that growth hormone-releasing hormone (GHRH) antagonists, suc

226 eurons, and two growth-stimulatory peptides, growth hormone-releasing hormone (GHRH) for GHRH-neurons

227 Agonists of growth hormone-releasing hormone (GHRH) have been previo

228 Growth hormone-releasing hormone (GHRH) is a hypothalami

229 Hypothalamic growth hormone-releasing hormone (GHRH) neurons orchestr

230 It has been shown that growth hormone-releasing hormone (GHRH) reduces cardiomy

231 The hypothalamic growth hormone-releasing hormone (GHRH) regulates the re

232 ith corticotropin-releasing factor (CRF) and growth hormone-releasing hormone (GHRH), suggesting nove

233 In view of the multiple activities of growth hormone-releasing hormone (GHRH), we hypothesized

234 Tesamorelin, a growth hormone-releasing hormone analog, specifically ta

235 The beneficial effects of agonists of growth hormone-releasing hormone receptor (GHRH-R) in he

236 re transplantation using a potent agonist of growth-hormone-releasing hormone (GHRH) to promote islet

237 ntrolled studies of the effects of long-term growth hormone replacement on fracture risk in adult pat

238 Our results suggest that growth hormone replacement therapy could be protective a

239 es chronic systemic inflammation, leading to growth hormone resistance and impaired linear growth.

240 alamic amenorrhoea; a nutritionally acquired growth-hormone resistance leading to low concentrations

241 pmental maturation of hepatic IGF-1 intron 2 growth hormone response element (IN2GHRE) histone methyl

242 stal weak enhancer (IGF-1 5'-upstream region growth hormone response element; 5URGHRE) as a GHRE spec

243 lly regulated by growth hormone (GH) through growth hormone response elements (GHREs).

244 ine, norepinephrine, glucagon, cortisol, and growth hormone responses were similarly reduced after al

245 HIIT suppressed cortisol and growth hormone responses, but not catecholamine response

246 ine, norepinephrine, glucagon, cortisol, and growth hormone responses.

247 and exhibited less robust corticosterone and growth hormone responses.

248 Benefits of recombinant human growth hormone (rhGH) alone or combined with glutamine i

249 for the quantification of recombinant human growth hormone (rhGH) in serum has been developed using

250 Somatropin (i.e., recombinant human growth hormone, rhGH) modified with the chelating agent

251 g periods and acts through its receptor, the growth hormone secretagogue 1a (GHSR1a), to promote food

252 ained another unapproved drug, including the growth hormone secretagogue ibutamoren, the peroxisome p

253 The truncated non-signaling ghrelin receptor growth hormone secretagogue R1b (GHS-R1b) has been sugge

254 Ghrelin's effect is mediated by its receptor Growth Hormone Secretagogue Receptor (GHS-R), but the ph

255 y format designed for the early detection of growth hormone secretagogue receptor (GHS-R1a) antagonis

256 lates hunger signals in the hypothalamus via growth hormone secretagogue receptor (GHS-R1a).

257 Growth hormone secretagogue receptor (GHSR) 1a is the on

258 The ghrelin receptor or growth hormone secretagogue receptor (GHSR) is a G-prote

259 ells produce ghrelin and delta-cells express growth hormone secretagogue receptor (GHSR), suggesting

260 ding to the only known ghrelin receptor, the growth hormone secretagogue receptor (GHSR).

261 actions of ghrelin are mediated through the growth hormone secretagogue receptor 1a (ghrelin recepto

262 The ghrelin receptor, also known as the growth hormone secretagogue receptor 1a (GHS-R1a), is a

263 by the stomach and acts at its receptor, the growth hormone secretagogue receptor 1a (GHSR1a), in the

264 n-KO mice and C57BL/6N mice administered the growth hormone secretagogue receptor agonist HM01 or veh

265 modeling, we demonstrate that binding to the growth hormone secretagogue receptor is accompanied by a

266 ility by activating KATP conductance via the growth hormone secretagogue receptor subtype 1a-Galphai

267 Ghrelin, the natural ligand of the growth hormone secretagogue receptor type 1a (GHS-R1a),

268 tion of a postsynaptic ghrelin receptor, the growth hormone secretagogue receptor type 1a (GHS-R1a),

269 The growth hormone secretagogue receptor, GHSR1a, mediates t

270 Growth hormone secretagogue receptors (GHSRs) in the cen

271 ly by the expression of the ghrelin receptor growth hormone secretagogue type 1a (GHS-R1a) in the hyp

272 ange of product variants in samples of human growth hormone secreted from Pichia pastoris.

273 Growth hormone-secreting (GH-secreting) pituitary tumors

274 ge repair pathways were affected by SCNAs in growth hormone-secreting (GH-secreting) somatotroph aden

275 IP) mutation-induced aggressive, young-onset growth hormone-secreting pituitary tumors are not fully

276 Growth hormone-secreting tumors account for 8% to 16% of

277 otropic effects including the stimulation of growth hormone secretion and subsequent increase of insu

278 ed receptor GHS-R1a mediates ghrelin-induced growth hormone secretion, food intake, and reward-seekin

279 number of physiological processes including growth hormone secretion, food intake, as well as energy

280 tial for intracellular protein sorting, cell growth, hormone secretion, and neurotransmission.

281 /-) mice had increased activation of hepatic growth hormone-signal transducer and activator of transc

282 mportant for GI health, nutrient harvest and growth hormone signaling, including decreased abundance

283 ed on the responses of the liver lincRNAs to growth hormone stimulation, which imparts clinically rel

284 Short-term growth hormone substitution might improve liver repopula

285 ence rate was lower in patients who received growth hormone than in those who did not (fracture incid

286 We further showed using murine growth hormone that postnatal intervention with both the

287 Starting growth hormone therapy before the onset of osteoporosis

288 Recombinant human growth hormone therapy of children with idiopathic short

289 Deciding when to pursue recombinant human growth hormone therapy to increase adult height is contr

290 ntiepileptic drugs and the efficacy of human growth hormone therapy, and few data are available for t

291 y and the evaluation of the effectiveness of growth hormone therapy.

292 Application of IGF-1 and growth hormone to human meibomian gland epithelial cells

293 between patients who did and did not receive growth hormone treatment in the subgroup of patients wit

294 Growth hormone treatment may be considered in some child

295 We assessed the effect of growth hormone treatment on fracture risk in patients wi

296 The effect of growth hormone treatment on fracture risk was assessed b

297 ces might miss the opportunity for effective growth hormone treatment.

298 Cytokines and growth hormones typically activate STATs and could there

299 epends on the action of the gibberellin (GA) growth hormones, which promote cell production in the ro

300 e expression of Pit1, Zbtb20, prolactin, and growth hormone, while its overexpression enhanced the le